血液学の最新論文（2018年4月リリース分）New reports on Hematology
Leukemia
- Blood Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. 131(17):1910-1919 O'Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC
- Blood Low catalase expression confers redox hypersensitivity and identifies an indolent clinical behavior in CLL. 131(17):1942-1954 Cavallini C, Chignola R, Dando I, Perbellini O, Mimiola E, Lovato O, Laudanna C, Pizzolo G, Donadelli M, Scupoli MT
- Blood Plasma cell leukemia presenting as “lymphocytosis”. 131(17):1994 Li S, Xu J
- Blood Gene mutations in lenalidomide-treated CLL. 131(16):1769-1771 Mauro FR, Foà R
- Blood A fellowship of Ring1 maintains AML stem cells. 131(16):1771-1773 Heery DM
- Blood Enhancer dysfunction in leukemia. 131(16):1795-1804 Bhagwat AS, Lu B, Vakoc CR
- Blood Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. 131(16):1820-1832 Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A
- Blood Ring1A and Ring1B inhibit expression of Glis2 to maintain murine MOZ-TIF2 AML stem cells. 131(16):1833-1845 Shima H, Takamatsu-Ichihara E, Shino M, Yamagata K, Katsumoto T, Aikawa Y, Fujita S, Koseki H, Kitabayashi I
- Blood Identification of novel recurrent CPSF6-RARG fusions in acute myeloid leukemia resembling acute promyelocytic leukemia. 131(16):1870-1873 Liu T, Wen L, Yuan H, Wang Y, Yao L, Xu Y, Cen J, Ruan C, Wu D, Chen S
- Blood Metabolic strugGLS after FLT3 inhibition in AML. 131(15):1631-1632 Taylor SJ, Steidl U
- Blood Venetoclax after idelalisib: relevant progress for CLL. 131(15):1632-1633 Bosch F, Hallek M
- Blood Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. 131(15):1639-1653 Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, Basheer F, Marando L, Di Lisio L, Dias JML, Yun H, Sasca D, Horton SJ, Vassiliou G, Frezza C, Huntly BJP
- Blood Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. 131(15):1704-1711 Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, Chyla B, Zhou L, Agarwal S, Waskiewicz T, Verdugo M, Humerickhouse RA, Potluri J, Wierda WG, Davids MS
- Blood LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. 131(15):1730-1742 Cusan M, Cai SF, Mohammad HP, Krivtsov A, Chramiec A, Loizou E, Witkin MD, Smitheman KN, Tenen DG, Ye M, Will B, Steidl U, Kruger RG, Levine RL, Rienhoff HY Jr, Koche RP, Armstrong SA
- Blood The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia. 131(15):1755-1758 Schliffke S, Buhs S, Bolz S, Gerull H, von Wenserski L, Riecken K, Fehse B, Nollau P, Binder M
- Blood Blinatumomab for MRD+ B-ALL: the evidence strengthens. 131(14):1497-1498 Brown P
- Blood Et tu, E2F1? The assassins of CML stem cells. 131(14):1499-1500 Krause DS
- Blood The interplay of leukemia cells and the bone marrow microenvironment. 131(14):1507-1511 Duarte D, Hawkins ED, Lo Celso C
- Blood Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. 131(14):1522-1531 Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC
- Blood hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival. 131(14):1532-1544 Pellicano F, Park L, Hopcroft LEM, Shah MM, Jackson L, Scott MT, Clarke CJ, Sinclair A, Abraham SA, Hair A, Helgason GV, Aspinall-O'Dea M, Bhatia R, Leone G, Kranc KR, Whetton AD, Holyoake TL
- Blood Integrated molecular profiling of juvenile myelomonocytic leukemia. 131(14):1576-1586 Murakami N, Okuno Y, Yoshida K, Shiraishi Y, Nagae G, Suzuki K, Narita A, Sakaguchi H, Kawashima N, Wang X, Xu Y, Chiba K, Tanaka H, Hama A, Sanada M, Ito M, Hirayama M, Watanabe A, Ueno T, Kojima S, Aburatani H, Mano H, Miyano S, Ogawa S, Takahashi Y, Muramatsu H
- Blood Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. 131(14):1617-1621 Wierz M, Pierson S, Guyonnet L, Viry E, Lequeux A, Oudin A, Niclou SP, Ollert M, Berchem G, Janji B, Guérin C, Paggetti J, Moussay E
- Br J Haematol Tumour genesis syndrome in relapsed B lymphoblastic leukaemia. 181(2):160 Shrubsole C, Collin M
- Br J Haematol Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study. 181(2):205-214 Østgård LSG, Nørgaard M, Pedersen L, Østgård RD, Medeiros BC, Overgaard UM, Schöllkopf C, Severinsen M, Marcher CW, Jensen MK
- Br J Haematol In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. 181(2):229-233 Rigolin GM, Saccenti E, Guardalben E, Cavallari M, Formigaro L, Zagatti B, Visentin A, Mauro FR, Lista E, Bassi C, Lupini L, Quaglia FM, Urso A, Bardi MA, Bonaldi L, Volta E, Tammiso E, Ilari C, Cafforio L, Melandri A, Cavazzini F, Negrini M, Semenzato G, Trentin L, Foà R, Cuneo A
- Br J Haematol Treatment of relapsed/refractory acute myeloid leukaemia in adults. 181(1):27-37 Rashidi A, Weisdorf DJ, Bejanyan N
- Br J Haematol Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword. 181(1):38-53 Hobo W, Hutten TJA, Schaap NPM, Dolstra H
- Br J Haematol Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia. 181(1):97-101 Crassini KR, Zhang E, Balendran S, Freeman JA, Best OG, Forsyth CJ, Mackinlay NJ, Han P, Stevenson WS, Mulligan SP
- Haematologica Bendamustine plus rituximab in chronic lymphocytic leukemia: is there life in the old dog yet? 103(4):563-564 Wendtner CM
- Haematologica The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. 103(4):565-574 Marke R, van Leeuwen FN, Scheijen B
- Haematologica Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndrome. 103(4):614-625 Thivakaran A, Botezatu L, Hönes JM, Schütte J, Vassen L, Al-Matary YS, Patnana P, Zeller A, Heuser M, Thol F, Gabdoulline R, Olberding N, Frank D, Suslo M, Köster R, Lennartz K, Görgens A, Giebel B, Opalka B, Dührsen U, Khandanpour C
- Haematologica Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. 103(4):626-633 Weinberg OK, Gibson CJ, Blonquist TM, Neuberg D, Pozdnyakova O, Kuo F, Ebert BL, Hasserjian RP
- Haematologica Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. 103(4):634-644 Sinclair PB, Blair HH, Ryan SL, Buechler L, Cheng J, Clayton J, Hanna R, Hollern S, Hawking Z, Bashton M, Schwab CJ, Jones L, Russell LJ, Marr H, Carey P, Halsey C, Heidenreich O, Moorman AV, Harrison CJ
- Haematologica Prevalence and characteristics of metabolic syndrome in adults from the French childhood leukemia survivors’ cohort: a comparison with controls from the French population. 103(4):645-654 Oudin C, Berbis J, Bertrand Y, Vercasson C, Thomas F, Chastagner P, Ducassou S, Kanold J, Tabone MD, Paillard C, Poirée M, Plantaz D, Dalle JH, Gandemer V, Thouvenin S, Sirvent N, Saultier P, Béliard S, Leverger G, Baruchel A, Auquier P, Pannier B, Michel G
- Haematologica Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients. 103(4):666-678 Arvidsson G, Henriksson J, Sander B, Wright AP
- Haematologica Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin. 103(4):688-697 Dürr C, Hanna BS, Schulz A, Lucas F, Zucknick M, Benner A, Clear A, Ohl S, Öztürk S, Zenz T, Stilgenbauer S, Li-Weber M, Krammer PH, Gribben JG, Lichter P, Seiffert M
- Haematologica Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. 103(4):698-706 Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V
- Haematologica Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo. 103(4):e147-e150 Kerstjens M, Pinhancos SS, Castro PG, Schneider P, Wander P, Pieters R, Stam RW
- Haematologica The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells ex vivo but fails to prevent leukemia development in a murine model. 103(4):e154-e157 Wierz M, Pierson S, Chouha N, Désaubry L, François JH, Berchem G, Paggetti J, Moussay E
- Haematologica No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. 103(4):e158-e161 Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton LA, Scarfo L, Davis Z, Yan XJ, Plevova K, Sandberg Y, Vojdeman FJ, Tzenou T, Chu CC, Veronese S, Mansouri L, Smedby KE, Giudicelli V, Nguyen-Khac F, Panagiotidis P, Juliusson G, Anagnostopoulos A, Lefranc MP, Trentin L, Catherwood M, Montillo M, Niemann CU, Langerak AW, Pospisilova S, Stavroyianni N, Chiorazzi N, Oscier D, Jelinek DF, Shanafelt T, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K
- J Clin Oncol IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. 36(12):1240-1249 Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, Eckert C, Te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M; TRANSCALL Consortium; International BFM Study Group
- J Clin Oncol Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy. 36(12):1250-1256 Berman E, Druker BJ, Burwick R
- J Clin Oncol Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia. 36(10):1007-1016 Bhayadia R, Krowiorz K, Haetscher N, Jammal R, Emmrich S, Obulkasim A, Fiedler J, Schwarzer A, Rouhi A, Heuser M, Wingert S, Bothur S, Döhner K, Mätzig T, Ng M, Reinhardt D, Döhner H, Zwaan CM, van den Heuvel Eibrink M, Heckl D, Fornerod M, Thum T, Humphries RK, Rieger MA, Kuchenbauer F, Klusmann JH
- Lancet Chronic lymphocytic leukaemia 391(10129):1524-1537 Michael Hallek, Tait D Shanafelt, Barbara Eichhorst
- Lancet Haematol Conditioning intensity in HCT for AML: the jury is still out. 5(4):e132-e133 Craddock C
- Lancet Haematol Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. 5(4):e161-e169 Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, Stadler M, Schäfer-Eckart K, Bätzel M, Eich H, Stuschke M, Engenhart-Cabillic R, Krause M, Dreger P, Neubauer A, Ehninger G, Beelen D, Berdel WE, Siepmann T, Stelljes M, Bornhäuser M
- Lancet Haematol Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. 5(4):e170-e180 Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadh S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ
- Lancet Oncol Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. 19(4):486-496 Burris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O'Connor OA
- Lancet Oncol Dasatinib in paediatric chronic myeloid leukaemias. 19(4):e188 Venkatesan P
- Leukemia Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia. 32(4):855-864 Fujita S, Honma D, Adachi N, Araki K, Takamatsu E, Katsumoto T, Yamagata K, Akashi K, Aoyama K, Iwama A, Kitabayashi I
- Leukemia A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target. 32(4):865-873 Yan F, Shen N, Pang JX, Zhao N, Zhang YW, Bode AM, Al-Kali A, Litzow MR, Li B, Liu SJ
- Leukemia Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia. 32(4):874-881 Lhermitte L, Mejstrikova E, van der Sluijs-Gelling AJ, Grigore GE, Sedek L, Bras AE, Gaipa G, Sobral da Costa E, Novakova M, Sonneveld E, Buracchi C, de Sá Bacelar T, Te Marvelde JG, Trinquand A, Asnafi V, Szczepanski T, Matarraz S, Lopez A, Vidriales B, Bulsa J, Hrusak O, Kalina T, Lecrevisse Q, Martin Ayuso M, Brüggemann M, Verde J, Fernandez P, Burgos L, Paiva B, Pedreira CE, van Dongen JJM, Orfao A, van der Velden VHJ
- Leukemia Targeting acute myeloid leukemia by drug-induced c-MYB degradation. 32(4):882-889 Walf-Vorderwülbecke V, Pearce K, Brooks T, Hubank M, van den Heuvel-Eibrink MM, Zwaan CM, Adams S, Edwards D, Bartram J, Samarasinghe S, Ancliff P, Khwaja A, Goulden N, Williams G, de Boer J, Williams O
- Leukemia SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia. 32(4):890-899 Bu J, Chen A, Yan X, He F, Dong Y, Zhou Y, He J, Zhan D, Lin P, Hayashi Y, Sun Y, Zhang Y, Xiao Z, Grimes HL, Wang QF, Huang G
- Leukemia The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia. 32(4):911-919 Sanarico AG, Ronchini C, Croce A, Memmi EM, Cammarata UA, De Antoni A, Lavorgna S, Divona M, Giacò L, Melloni GEM, Brendolan A, Simonetti G, Martinelli G, Mancuso P, Bertolini F, Coco FL, Melino G, Pelicci PG, Bernassola F
- Leukemia RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia. 32(4):931-940 Jerchel IS, Hoogkamer AQ, Ariës IM, Steeghs EMP, Boer JM, Besselink NJM, Boeree A, van de Ven C, de Groot-Kruseman HA, de Haas V, Horstmann MA, Escherich G, Zwaan CM, Cuppen E, Koudijs MJ, Pieters R, den Boer ML
- Leukemia Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system. 32(4):941-951 Bornschein S, Demeyer S, Stirparo R, Gielen O, Vicente C, Geerdens E, Ghesquière B, Aerts S, Cools J, de Bock CE
- Leukemia Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. 32(4):960-970 Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K
- Leukemia Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity. 32(4):1041-1044 Marsilio S, Khiabanian H, Fabbri G, Vergani S, Scuoppo C, Montserrat E, Shpall EJ, Hadigol M, Marin P, Rai KR, Rabadan R, Devereux S, Pasqualucci L, Chiorazzi N
- Leukemia CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC. 32(4):1049-1052 Tirado-Gonzalez I, Czlonka E, Nevmerzhitskaya A, Soetopo D, Bergonzani E, Mahmoud A, Contreras A, Jeremias I, Platzbecker U, Bourquin JP, Kloz U, Van der Hoeven F, Medyouf H
Lymphoma
- Blood Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments. 131(17):1931-1941 Cho SY, Sung CO, Chae J, Lee J, Na D, Kang W, Kang J, Min S, Lee A, Kwak E, Kim J, Choi B, Kim H, Chuang JH, Pak HK, Park CS, Park S, Ko YH, Lee D, Roh J, Cho MS, Park S, Ju YS, Suh YS, Kong SH, Lee HJ, Keck J, Banchereau J, Liu ET, Kim WH, Park H, Yang HK, Kim JI, Lee C
- Blood Awakening exhausted NK cells in lymphomas. 131(16):1768-1769 Alinari L
- Blood Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. 131(16):1809-1819 Vari F, Arpon D, Keane C, Hertzberg MS, Talaulikar D, Jain S, Cui Q, Han E, Tobin J, Bird R, Cross D, Hernandez A, Gould C, Birch S, Gandhi MK
- Blood Testicular double-hit lymphoma in a patient with history of follicular lymphoma with high proliferation index. 131(16):1874 Chung BM, Zieske AW
- Blood Introduction to a review series on Hodgkin lymphoma: change is here. 131(15):1629-1630 Sehn LH
- Blood Lymphoma exosomes reprogram the bone marrow. 131(15):1635-1636 Whiteside TL
- Blood Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. 131(15):1654-1665 Mottok A, Steidl C
- Blood Balancing risk and benefit in early-stage classical Hodgkin lymphoma. 131(15):1666-1678 Bröckelmann PJ, Sasse S, Engert A
- Blood Optimizing therapy in advanced-stage Hodgkin lymphoma. 131(15):1679-1688 Lim SH, Johnson PWM
- Blood Transplant strategies in relapsed/refractory Hodgkin lymphoma. 131(15):1689-1697 Shah GL, Moskowitz CH
- Blood Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients. 131(15):1698-1703 Mehta-Shah N, Bartlett NL
- Blood ALK+ small cell variant of anaplastic large cell lymphoma with leukemic presentation. 131(15):1764 Jiang X, Zhou D
- Blood Monomorphic epitheliotropic intestinal T-cell lymphoma involving the central nervous system. 131(15):1765 Kubota Y, Kusaba K
- Br J Haematol Disease site as a determinant of survival outcome in patients with systemic anaplastic lymphoma kinase positive anaplastic large cell lymphoma with extranodal involvement: an analysis of 1306 cases from the US National Cancer Database. 181(2):196-204 Nguyen KA, Su C, Bai HX, Zhang Z, Xiao R, Karakousis G, Zhang PJ, Zhang G
- Br J Haematol Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK’s Haematological Malignancy Research Network (HMRN). 181(2):215-228 Smith A, Roman E, Appleton S, Howell D, Johnson R, Burton C, Patmore R
- Br J Haematol Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. 181(1):86-96 Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, Blaise D, Afanasyev B, Diez-Martin JL, Sierra J, Bloor A, Martinez C, Robinson S, Malladi R, El-Cheikh J, Corradini P, Montoto S, Dreger P, Sureda A
- Haematologica CD83 in Hodgkin lymphoma. 103(4):561-562 Küppers R
- Haematologica CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. 103(4):655-665 Li Z, Ju X, Lee K, Clarke C, Hsu JL, Abadir E, Bryant CE, Pears S, Sunderland N, Heffernan S, Hennessy A, Lo TH, Pietersz GA, Kupresanin F, Fromm PD, Silveira PA, Tsonis C, Cooper WA, Cunningham I, Brown C, Clark GJ, Hart DNJ
- Haematologica Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients. 103(4):666-678 Arvidsson G, Henriksson J, Sander B, Wright AP
- Haematologica Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. 103(4):679-687 Ji MM, Huang YH, Huang JY, Wang ZF, Fu D, Liu H, Liu F, Leboeuf C, Wang L, Ye J, Lu YM, Janin A, Cheng S, Zhao WL
- Haematologica Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. 103(4):e151-e153 Rimsza LM, Li H, Braziel RM, Spier CM, Persky DO, Dunlap J, LeBlanc M, Bartlett N, Leonard JP, Smith SM, Press OW, Friedberg JW
- J Clin Oncol Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. 36(11):1128-1139 Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM
- J Clin Oncol Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. 36(10):942-950 Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA
- Lancet Haematol Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. 5(4):e170-e180 Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadh S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ
- Lancet Oncol Predicting early relapse in follicular lymphoma: have we turned a corner? 19(4):441-442 Araf S, Okosun J, Fitzgibbon J
- Lancet Oncol Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. 19(4):486-496 Burris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O'Connor OA
- Lancet Oncol A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. 19(4):549-561 Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, Salles G
- N Engl J Med Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. 378(15):1396-1407 Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM
Myeloma
- Br J Haematol The importance of the peripheral blood film in indicating a diagnosis of multiple myeloma with cryoglobulinaemia. 181(1):10 Hunt S, Taylor J, Cochrane T
- Br J Haematol Molecular detection of minimal residual disease in multiple myeloma. 181(1):11-26 Bai Y, Orfao A, Chim CS
- Haematologica Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment. 103(4):707-716 Belloni D, Heltai S, Ponzoni M, Villa A, Vergani B, Pecciarini L, Marcatti M, Girlanda S, Tonon G, Ciceri F, Caligaris-Cappio F, Ferrarini M, Ferrero E
- Haematologica Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels. 103(4):e162-e164 Yadav P, Merz M, Mai EK, Försti A, Jauch A, Goldschmidt H, Hemminki K
- Leukemia Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. 32(4):971-978 Arana P, Paiva B, Cedena MT, Puig N, Cordon L, Vidriales MB, Gutierrez NC, Chiodi F, Burgos L, Anglada LL, Martinez-Lopez J, Hernandez MT, Teruel AI, Gironella M, Echeveste MA, Rosiñol L, Martinez R, Oriol A, De la Rubia J, Orfao A, Blade J, Lahuerta JJ, Mateos MV, San Miguel JF
- Leukemia Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. 32(4):979-985 Bringhen S, D'Agostino M, De Paoli L, Montefusco V, Liberati AM, Galieni P, Grammatico S, Muccio VE, Esma F, De Angelis C, Musto P, Ballanti S, Offidani M, Petrucci MT, Gaidano G, Corradini P, Palumbo A, Sonneveld P, Boccadoro M
- Leukemia Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. 32(4):986-995 Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A
- Leukemia Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 32(4):996-1002 Gullà A, Hideshima T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, Tai YT, Harada T, Morelli E, Amodio N, Carrasco R, Tagliaferri P, Munshi NC, Tassone P, Anderson KC
- Leukemia MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. 32(4):1003-1015 Botta C, Cucè M, Pitari MR, Caracciolo D, Gullà A, Morelli E, Riillo C, Biamonte L, Gallo Cantafio ME, Prabhala R, Mignogna C, Di Vito A, Altomare E, Amodio N, Di Martino MT, Correale P, Rossi M, Giordano A, Munshi NC, Tagliaferri P, Tassone P
- Leukemia Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. 32(4):1044-1048 Maura F, Petljak M, Lionetti M, Cifola I, Liang W, Pinatel E, Alexandrov LB, Fullam A, Martincorena I, Dawson KJ, Angelopoulos N, Samur MK, Szalat R, Zamora J, Tarpey P, Davies H, Corradini P, Anderson KC, Minvielle S, Neri A, Avet-Loiseau H, Keats J, Campbell PJ, Munshi NC, Bolli N
SCT
- Blood Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT. 131(16):1846-1857 Berger G, Kroeze LI, Koorenhof-Scheele TN, de Graaf AO, Yoshida K, Ueno H, Shiraishi Y, Miyano S, van den Berg E, Schepers H, van der Reijden BA, Ogawa S, Vellenga E, Jansen JH
- Br J Haematol Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. 181(1):86-96 Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, Blaise D, Afanasyev B, Diez-Martin JL, Sierra J, Bloor A, Martinez C, Robinson S, Malladi R, El-Cheikh J, Corradini P, Montoto S, Dreger P, Sureda A
- Lancet Haematol Conditioning intensity in HCT for AML: the jury is still out. 5(4):e132-e133 Craddock C
- Lancet Haematol Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. 5(4):e161-e169 Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, Stadler M, Schäfer-Eckart K, Bätzel M, Eich H, Stuschke M, Engenhart-Cabillic R, Krause M, Dreger P, Neubauer A, Ehninger G, Beelen D, Berdel WE, Siepmann T, Stelljes M, Bornhäuser M
- Leukemia Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. 32(4):986-995 Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A
HSC
- Blood Can genetics resolve what Notch does in HSCs? 131(15):1633-1635 Maillard I, Pear WS
- Lancet Haematol Conditioning intensity in HCT for AML: the jury is still out. 5(4):e132-e133 Craddock C
- Lancet Haematol Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. 5(4):e161-e169 Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, Stadler M, Schäfer-Eckart K, Bätzel M, Eich H, Stuschke M, Engenhart-Cabillic R, Krause M, Dreger P, Neubauer A, Ehninger G, Beelen D, Berdel WE, Siepmann T, Stelljes M, Bornhäuser M
- Leukemia Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. 32(4):986-995 Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A
Anemia
- Blood Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved? 131(17):1989-1992 Giammarco S, Peffault de Latour R, Sica S, Dufour C, Socie G, Passweg J, Kröger N, Petersen E, Van Lint MT, Oneto R, Signori A, Bacigalupo A; European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party
- Blood A Ser725Arg mutation in Band 3 abolishes transport function and leads to anemia and renal tubular acidosis. 131(15):1759-1763 Yang E, Seo-Mayer P, Lezon-Geyda K, Badior KE, Li J, Casey JR, Reithmeier RAF, Gallagher PG
- Blood A neonate presenting with jaundice, anemia, and thrombocytopenia. 131(14):1627 Hager HB, Andersen MT
- Br J Haematol Transcranial Doppler velocity among Jamaican children with sickle cell anaemia: determining the significance of haematological values and nutrition. 181(2):242-251 Rankine-Mullings AE, Morrison-Levy N, Soares D, Aldred K, King L, Ali S, Knight-Madden JM, Wisdom-Phipps M, Adams RJ, Ware RE, Reid M
- Lancet Haematol Sickle-cell anaemia needs more food? 5(4):e130-e131 Hyacinth HI
ITP
- Br J Haematol A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. 181(2):183-195 Rodeghiero F
- Br J Haematol Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia. 181(2):234-241 Nazy I, Kelton JG, Moore JC, Clare R, Horsewood P, Smith JW, Ivetic N, D'Souza V, Li N, Arnold DM